Virtuix to Host Investor Webinar on Growth Plans
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Should l Buy VTIX?
Source: Newsfilter
- Webinar Announcement: Virtuix will hold a virtual investor webinar on February 4, 2026, at 11:30 AM ET, hosted by Founder and CEO Jan Goetgeluk, to discuss the company's growth plans and dual-market strategy.
- Dual-Market Strategy: The company aims to combine high-volume consumer sales with high-margin defense contracts, leveraging AI-driven 3D reconstruction technology to accelerate product adoption across consumer, enterprise, and defense sectors, thereby enhancing overall market competitiveness.
- Q&A Session: The webinar will feature a question-and-answer session, allowing investors to submit questions in advance via email, which enhances interaction with management and boosts investor confidence.
- Innovation Showcase: Virtuix's
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTIX
Wall Street analysts forecast VTIX stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 6.430
Low
Averages
High
Current: 6.430
Low
Averages
High
No data
About VTIX
Virtuix Holdings Inc. is the creator of Omni, the premier brand of omni-directional treadmills that let players walk and run in 360 degrees inside virtual reality (VR) games, digital twins, and other applications. It offers various products that target a variety of industries, namely Omni Pro, Omni Arena, Omni One, and Virtual Terrain Walk (VTW). Omni Pro is its commercial-grade treadmill for enterprise use in arcades, VR centers, corporations, and research institutions. Omni Arena was launched as a turnkey attraction for the out-of-home entertainment industry. The attraction comprises four Omni Pro treadmills for multiplayer gaming and features weekly esports prize contests. Omni One is its most advanced treadmill, supporting full freedom of movement including crouching, kneeling, and jumping. It sells Omni One in three different versions: the complete Omni One system, Omni One Core, and Omni One Enterprise. VTW is its multi-user system for mission planning in the defense industry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Virtuix Omni One Evaluated for Medical Applications at FGCU
- Medical Application Potential: Virtuix's Omni One omni-directional treadmill system has been delivered to Florida Gulf Coast University for evaluation in physical therapy, occupational therapy, and neurological rehabilitation, showcasing its strong potential as a medical device that could significantly enhance patient recovery outcomes.
- Significant Market Opportunity: The global physical therapy market is projected to grow from $26 billion in 2025 to $50 billion by 2034, and Virtuix's technology is well-positioned to meet this rapidly growing demand, particularly in the context of an aging population and increasing chronic conditions, highlighting its strategic market significance.
- Educational Simulation Applications: Omni One is not only applicable for rehabilitation but also for simulation-based education, enabling learners to train in virtual environments, enhancing situational awareness and executive function, thereby further expanding Virtuix's market application scope.
- Diversified Market Strategy: Virtuix remains focused on consumer and defense markets, recently partnering with Meta to make Omni One compatible with Meta Quest headsets, thereby broadening its influence among the global XR user base and demonstrating the company's strategic positioning across multiple sectors.
See More
Virtuix Signs Research Agreement with Naval Postgraduate School
- Research Agreement: Virtuix has signed a Cooperative Research and Development Agreement with the Naval Postgraduate School in Monterey, California, marking the company's first formal research collaboration with the U.S. Navy, which is expected to enhance its technology applications in military training and simulation.
- Technology Delivery: Under the agreement, Virtuix will deliver an Omni One system to the Modeling, Virtual Environments, and Simulation Institute at NPS, aimed at assessing the suitability and effectiveness of small-footprint, omni-directional navigation technology for various military tasks.
- Market Potential: This agreement not only provides Virtuix with an opportunity to enter the military market but also lays the groundwork for future product development and market expansion, enhancing the company's competitiveness in related fields.
- Stock Price Reaction: Following the announcement, Virtuix's stock price rose to $6.72 in pre-market trading, reflecting a positive market response to the collaboration agreement and potentially boosting investor confidence in the company's future prospects.
See More
VIRTUIX ENTERS INTO RESEARCH AND DEVELOPMENT PARTNERSHIP WITH U.S. NAVY
- Partnership Announcement: Virtuix has signed a cooperative research and development agreement with the U.S. Navy.
- Focus Areas: The agreement aims to explore advancements in virtual reality and simulation technologies for military applications.
See More
Virtuix Holdings Reports Q3 Financials Amid Direct Listing Plans
- Financial Overview: Virtuix Holdings Inc. reported a Q3 GAAP EPS of -$0.09, indicating challenges in profitability that could undermine investor confidence moving forward.
- Revenue Performance: The company generated $1 million in revenue for Q3, which, while showing some growth compared to the previous year, remains insufficient and highlights the difficulties faced in a competitive market.
- Nine-Month Revenue: Year-to-date, Virtuix Holdings has accumulated $3 million in revenue, suggesting a significant gap from annual revenue targets that may impact future financing capabilities.
- Direct Listing Plans: The company is pursuing a direct listing despite the challenges of low revenue and a risky transition, a strategy that could attract investors interested in emerging markets but also increases market uncertainty.
See More
Virtuix Reports 41% Revenue Growth to $3.0 Million
- Significant Revenue Growth: For the nine months ended December 31, 2025, Virtuix reported net sales of $3.0 million, a 41% increase driven by strong demand for the Omni One system and a successful holiday season, indicating the company's growth potential in the virtual reality market.
- Improved Gross Margin: The gross margin for the nine months improved from -17% in the prior year to 29%, attributed to the price increase of the Omni One system and reduced unit production costs, showcasing the company's success in cost control and pricing strategy.
- Substantial Decrease in Operating Expenses: Operating expenses for the nine months ended December 31, 2025, decreased by 45% to $6.3 million, primarily due to significant reductions in general and administrative expenses, reflecting effective measures in enhancing efficiency and controlling costs.
- International Market Expansion: Through collaboration with Meta, Virtuix has broadened the market reach of Omni One, potentially attracting 6 million active users, further driving the company's growth strategy in the global virtual reality market.
See More
New Show to Air Tonight on Bloomberg Television
- Global Broadcast Expansion: New to The Street's latest episode will air tonight at 6:30 PM EST on Bloomberg Television, extending its reach to the U.S., MENA, and Latin America, thereby enhancing international investor engagement and broadening its audience base.
- Biotech Advancements: BioVie Inc. is advancing a clinical trial for Parkinson's disease with 60 patients enrolled, expecting topline data in May 2026, which could significantly bolster its market position in the biopharmaceutical sector if successful.
- Obstructive Sleep Apnea Solutions: Vivos Therapeutics Inc.'s FDA-cleared non-surgical oral appliance aims to provide a long-term solution for the estimated one billion people affected by OSA globally, with strategic growth initiatives targeting direct-to-patient markets.
- Virtual Reality Market Growth: Virtuix Holdings Inc.'s Omni One platform has reported a 138% year-over-year growth in the gaming and fitness sectors, with production capacity supporting potential annual revenues of up to $100 million, indicating strong demand in both consumer and defense markets.
See More
Virtuix Omni One Evaluated for Medical Applications at FGCU
- Medical Application Potential: Virtuix's Omni One omni-directional treadmill system has been delivered to Florida Gulf Coast University for evaluation in physical therapy, occupational therapy, and neurological rehabilitation, showcasing its strong potential as a medical device that could significantly enhance patient recovery outcomes.
- Significant Market Opportunity: The global physical therapy market is projected to grow from $26 billion in 2025 to $50 billion by 2034, and Virtuix's technology is well-positioned to meet this rapidly growing demand, particularly in the context of an aging population and increasing chronic conditions, highlighting its strategic market significance.
- Educational Simulation Applications: Omni One is not only applicable for rehabilitation but also for simulation-based education, enabling learners to train in virtual environments, enhancing situational awareness and executive function, thereby further expanding Virtuix's market application scope.
- Diversified Market Strategy: Virtuix remains focused on consumer and defense markets, recently partnering with Meta to make Omni One compatible with Meta Quest headsets, thereby broadening its influence among the global XR user base and demonstrating the company's strategic positioning across multiple sectors.
See More
Virtuix Signs Research Agreement with Naval Postgraduate School
- Research Agreement: Virtuix has signed a Cooperative Research and Development Agreement with the Naval Postgraduate School in Monterey, California, marking the company's first formal research collaboration with the U.S. Navy, which is expected to enhance its technology applications in military training and simulation.
- Technology Delivery: Under the agreement, Virtuix will deliver an Omni One system to the Modeling, Virtual Environments, and Simulation Institute at NPS, aimed at assessing the suitability and effectiveness of small-footprint, omni-directional navigation technology for various military tasks.
- Market Potential: This agreement not only provides Virtuix with an opportunity to enter the military market but also lays the groundwork for future product development and market expansion, enhancing the company's competitiveness in related fields.
- Stock Price Reaction: Following the announcement, Virtuix's stock price rose to $6.72 in pre-market trading, reflecting a positive market response to the collaboration agreement and potentially boosting investor confidence in the company's future prospects.
See More
VIRTUIX ENTERS INTO RESEARCH AND DEVELOPMENT PARTNERSHIP WITH U.S. NAVY
- Partnership Announcement: Virtuix has signed a cooperative research and development agreement with the U.S. Navy.
- Focus Areas: The agreement aims to explore advancements in virtual reality and simulation technologies for military applications.
See More
Virtuix Holdings Reports Q3 Financials Amid Direct Listing Plans
- Financial Overview: Virtuix Holdings Inc. reported a Q3 GAAP EPS of -$0.09, indicating challenges in profitability that could undermine investor confidence moving forward.
- Revenue Performance: The company generated $1 million in revenue for Q3, which, while showing some growth compared to the previous year, remains insufficient and highlights the difficulties faced in a competitive market.
- Nine-Month Revenue: Year-to-date, Virtuix Holdings has accumulated $3 million in revenue, suggesting a significant gap from annual revenue targets that may impact future financing capabilities.
- Direct Listing Plans: The company is pursuing a direct listing despite the challenges of low revenue and a risky transition, a strategy that could attract investors interested in emerging markets but also increases market uncertainty.
See More
Virtuix Reports 41% Revenue Growth to $3.0 Million
- Significant Revenue Growth: For the nine months ended December 31, 2025, Virtuix reported net sales of $3.0 million, a 41% increase driven by strong demand for the Omni One system and a successful holiday season, indicating the company's growth potential in the virtual reality market.
- Improved Gross Margin: The gross margin for the nine months improved from -17% in the prior year to 29%, attributed to the price increase of the Omni One system and reduced unit production costs, showcasing the company's success in cost control and pricing strategy.
- Substantial Decrease in Operating Expenses: Operating expenses for the nine months ended December 31, 2025, decreased by 45% to $6.3 million, primarily due to significant reductions in general and administrative expenses, reflecting effective measures in enhancing efficiency and controlling costs.
- International Market Expansion: Through collaboration with Meta, Virtuix has broadened the market reach of Omni One, potentially attracting 6 million active users, further driving the company's growth strategy in the global virtual reality market.
See More
New Show to Air Tonight on Bloomberg Television
- Global Broadcast Expansion: New to The Street's latest episode will air tonight at 6:30 PM EST on Bloomberg Television, extending its reach to the U.S., MENA, and Latin America, thereby enhancing international investor engagement and broadening its audience base.
- Biotech Advancements: BioVie Inc. is advancing a clinical trial for Parkinson's disease with 60 patients enrolled, expecting topline data in May 2026, which could significantly bolster its market position in the biopharmaceutical sector if successful.
- Obstructive Sleep Apnea Solutions: Vivos Therapeutics Inc.'s FDA-cleared non-surgical oral appliance aims to provide a long-term solution for the estimated one billion people affected by OSA globally, with strategic growth initiatives targeting direct-to-patient markets.
- Virtual Reality Market Growth: Virtuix Holdings Inc.'s Omni One platform has reported a 138% year-over-year growth in the gaming and fitness sectors, with production capacity supporting potential annual revenues of up to $100 million, indicating strong demand in both consumer and defense markets.
See More
